of the Federal Aviation Regulations (14 CFR 21.197 and 21.199) to operate the airplane to a location where the requirements of this AD can be accomplished.

(f) An alternative method of compliance or adjustment of the initial or repetitive compliance times that provides an equivalent level of safety may be approved by the Manager, Airplane Certification Office (ACO), FAA, 2601 Meacham Boulevard, Fort Worth, Texas 76193–0150. The request shall be forwarded through an appropriate FAA Maintenance Inspector, who may add comments and then send it to the Manager, Fort Worth ACO. Alternative methods of compliance approved in accordance with AD 93–19–06 (superseded by this action) are not considered approved as alternative methods of compliance with this AD.

Note 4: Information concerning the existence of approved alternative methods of compliance with this AD, if any, may be obtained from the Fort Worth ACO.

(g) The inspections required by this AD shall be done in accordance with Fairchild Service Bulletin 26–56–20–042, Issued: November 28, 1988; Revised: February 7, 1991, Fairchild Service Bulletin 226–56–001, Issued: February 2, 1983; Revised: November 26, 1991, Fairchild Service Bulletin 227–56–001, Issued: February 2, 1983; Revised: November 26, 1991, Fairchild Service Bulletin 226–56–002, Issued: March 3, 1983; Revised: May 29, 1992, Fairchild Service Bulletin 227–56–002, Issued: January 5, 1984; Revised: May 29, 1992, and April 1, 1993, Fairchild Service Bulletin 226–56–003, Issued: September 13, 1984; Revised: November 2, 1989, Fairchild Service Bulletin 227–56–003, Issued: September 13, 1984; Revised: November 2, 1989, and Fairchild Service Bulletin 26–56–10–038, Issued: October 8, 1984; Revised: February 7, 1991, as applicable. This incorporation by reference was previously approved by the Director of the Federal Register in accordance with 5 U.S.C. 552 (a) and 1 CFR part 51. Copies may be obtained from Fairchild Aircraft, P.O. Box 790490, San Antonio, Texas 78279–0490. Copies may be inspected at the FAA, Central Region, Office of the Assistant Chief Counsel, Room 1558, 601 E. 12th Street, Kansas City, Missouri, or at the Office of the Federal Register, 800 North Capitol Street, NW., suite 700, Washington, DC.

(h) This amendment (39–9774) supersedes AD 93–19–06, Amendment 39–8705.

(i) This amendment (39–9774) becomes effective on November 14, 1996.

Issued in Kansas City, Missouri, on September 19, 1996.

Michael Gallagher,

Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. 96–24886 Filed 9–27–96; 8:45 am]

BILLING CODE 4910–13–U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 558

New Animal Drugs For Use In Animal Feeds; Monensin

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Elanco Animal Health, Division of Eli Lilly and Co. The supplemental NADA provides for monensin Type A medicated articles to be used to make free-choice Type C medicated feeds for pasture cattle weighing less than 400 pounds for increased rate of weight gain.

EFFECTIVE DATE: September 30, 1996.

FOR FURTHER INFORMATION CONTACT: Jack Caldwell, Center for Veterinary Medicine (HFV–126), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1638.

SUPPLEMENTARY INFORMATION: Elanco Animal Health, Division of Eli Lilly and Co., Lilly Corporate Center, Indianapolis, IN 46285, filed supplemental NADA 95–735, which provides for use of a monensin Type A medicated article to make a monensin Type C medicated feed/free-choice mineral granule containing 1620 grams monensin per ton (g/t) to be fed at 50 to 200 milligrams per head per day free-choice to pasture cattle (slaughter, stocker, feeder, and dairy and beef replacement heifers) for increased rate of weight gain.

The supplemental NADA provides for removal of the restriction concerning use of the product for animals weighing less than 400 pounds body weight. The supplemental NADA is approved as of September 30, 1996, and the regulations are amended in 21 CFR 558.355(f)(3)(x)(c) to reflect the approval.

Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), approval of this supplemental NADA does not qualify for marketing exclusivity because the supplement does not contain reports of new clinical or field investigations (other than bioequivalence or residue studies) or new human food safety studies (other than bioequivalence or residue studies) essential to the approval and conducted or sponsored by the applicant.

Approval of this supplemental NADA does not require a freedom of information (FOI) summary because the approval relies on data and information filed to support a previously approved supplement. FOI summaries for prior approvals may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, from 9 a.m. to 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.24(d)(1)(i) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

List of Subjects in 21 CFR Part 558

Animal drugs, Animal feeds

Therefore, under the Federal Food, Drug, and Cosmetic Act and under the authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is amended as follows:

PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

1. The authority citation for 21 CFR part 558 continues to read as follows:

Authority: Secs. 512, 701 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b, 371).

§ 558.355 [Amended]

2. Section 558.355 *Monensin* is amended in paragraph (f)(3)(x)(*c*) in the first sentence by removing the phrase ''weighing more than 400 pounds''.

Dated: September 3, 1996.

Robert C. Livingston,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 96–24965 Filed 9–27–96; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

21 CFR Part 1313

[DEA Number 110F]

RIN 1117–AA21

Distribution of Chemical Import/Export Declaration

AGENCY: Drug Enforcement Administration (DEA), Justice.

ACTION: Final rule.